News
Despite advances in defibrillation technology, shock-refractory ventricular fibrillation remains common during out-of-hospital cardiac arrest. Double sequential external defibrillation (DSED ...
In order to remove obstacles preventing immediate defibrillation, the medical community and the media worked together to highlight the importance of public access defibrillation. Under increasing ...
Delayed defibrillation was also associated with a significantly lower likelihood of return of spontaneous circulation (adjusted odds ratio, 0.55; 95% CI, 0.49 to 0.62; P<0.001) and survival at 24 ...
CPR Therapeutics Inc. announced today that the company has received a continuation U.S. patent for technology that underlies ...
Researchers used data from the Portland Cardiac Arrest Epidemiologic Registry, which comprehensively recorded the placement position of defibrillation pads from July 1, 2019, through June 30, 2023.
The US Food and Drug Administration (FDA) has granted approval for Medtronic’s OmniaSecure defibrillation lead intended for insertion in the right ventricle. This new 4.7 French (1.6mm ...
Vermont Business Magazine CPR Therapeutics Inc of Putney announced Monday that the company has received a continuation U.S. patent for technology that underlies its multimodal cardiopulmonary ...
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025 ...
Both cardioversion and defibrillation can use a manual device to administer electrical impulses to the heart. According to a 2021 article, the main difference between them is the timing and method ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results